Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof

US9254288B2 · kind B2 · utility

Assignees

• The Translational Genomics Research Institute · US
• Queensland University of Technology · AU

Inventor

• Pamela Pollock · Forsayth, AU

Key dates

• Filing date: May 7, 2013
• Grant date: Feb 9, 2016
• Expiry date: Sep 13, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, using these molecules and fragments thereof, and kits for employing these methods and compositions.